These findings highlight the intricate relationship between TGF-β signaling and lipotoxicity in liver disease progression, and point to potential therapeutic avenues by targeting specific Smad3 isoforms and TGF-β pathways to mitigate the impact of lipotoxicity in MASH and related conditions. The gene discussed is SMAD3; the disease is metabolic dysfunction-associated steatohepatitis.